A5005823254- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Cancer Genomics and Diagnostics
- Esophageal Cancer Research and Treatment
- Radiopharmaceutical Chemistry and Applications
- Ferroptosis and cancer prognosis
- Cancer Treatment and Pharmacology
- Cancer Cells and Metastasis
- Lung Cancer Treatments and Mutations
- Cancer-related molecular mechanisms research
- RNA modifications and cancer
- Cancer, Lipids, and Metabolism
- Cancer, Hypoxia, and Metabolism
- Metabolomics and Mass Spectrometry Studies
Fudan University Shanghai Cancer Center
2023-2024
Shanghai Medical College of Fudan University
2024
Ruijin Hospital
2019
Abstract Background Gene mutations play a crucial role in the occurrence and development of tumors, particularly breast cancer (BC). Neoadjuvant therapy (NAT) has shown greater clinical benefit HER2‐positive cancer. However, further investigation is needed to fully understand correlation between genetic NAT efficacy long‐term prognosis BC. Methods This was retrospective cohort study 222 patients receiving 2017 2021 Department Breast Surgery Fudan University Shanghai Cancer Center. Tumor...
Abstract p95HER2 isoform is a truncated form of HER2 that retains the C terminal domain but lacks an N trastuzumab binding site. From 2014 to 2016, we assessed expression in 59 HER2‐positive breast cancer patients from FUSCC. The median follow‐up was 54 months. In our study, 19 (32.2%) were positive. p95HER2‐positive rate higher premenopausal than postmenopausal (68.4% vs. 31.6%, P = .026). positive found more and associated with worse DFS (hazard ratio, 2.21; 95% CI, 1.06–4.61; .034),...
Abstract Background: Although trastuzumab and tyrosine inhibitors combined with neoadjuvant chemotherapy could significantly improve patients' pathological complete response (pCR) rate, nearly half of the patients not achieve remission. Our objective was to explore relationship between metabolic signaling pathway changes therapeutic efficacy in receiving therapy for HER2-positive breast cancer. Methods: Core needle biopsy specimens from cancer who underwent radical mastectomy at Fudan...
Abstract Background: -HER2-positive breast cancer subtype accounted for around 15-20% of all cancer. -The introduction HER2-targeted therapy such as trastuzumab and pertuzumab has remarkably increased the patients’ prognosis HER2-positive -However, resistance exists due to impaired drug binding HER2 receptor constitutive activation downstream signaling pathways. -P95HER2 isoform is a truncated form that retains C terminal domain but lacks an N site, leading in -A new P95HER2 antibody...
Abstract Background: -Trastuzumab-based neoadjuvant chemotherapy has shown to have remarkable clinical benefits for HER2-positive breast cancer patients who had higher tumor burden. -Patients achieved pathological complete response (pCR) are known better prognosis. -However, certain little or not sensitive trastuzumab-based treatment regimens. -Understanding the mechanism of trastuzumab resistance is crucial development new therapeutic strategy. Objectives: To investigate role TCEAL9 in...
Abstract ABSTRACT Background: Breast cancer has become the most common worldwide and triple-negative breast (TNBC) is aggressive subtype due to lacks of hormone receptors HER2 expression. Increasing rate metastasis also need be solved. Nearly one in four patients developed after treatment, which attributed 90% related death. Considering highly pattern TNBC, TNBC showed higher probability rather than other subtypes. Therefore, exploring more biomarkers therapeutic targets are on urgent....